--- title: "Health Care Down After Mixed Earnings - Health Care Roundup" description: "Health-care companies fell amid mixed earnings. Oscar Health shares rose slightly after the health insurer's outlook for moderating medical losses offset a wider fourth-quarter loss. CVS Health shares" type: "news" locale: "en" url: "https://longbridge.com/en/news/275520670.md" published_at: "2026-02-10T22:31:18.000Z" --- # Health Care Down After Mixed Earnings - Health Care Roundup > Health-care companies fell amid mixed earnings. Oscar Health shares rose slightly after the health insurer's outlook for moderating medical losses offset a wider fourth-quarter loss. CVS Health shares ticked down even after the drug-store chain and health insurer logged earnings ahead of analysts' expectations. Incyte slid after the maker of cancer drugs and other specialty pharmaceuticals forecast 2026 revenue short of Wall Street expectations. Write to Rob Curran at rob.curran@dowjones.com (END) Dow Jones Newswires 02-10-26 1730ET Health-care companies fell amid mixed earnings. Oscar Health shares rose slightly after the health insurer's outlook for moderating medical losses offset a wider fourth-quarter loss. CVS Health shares ticked down even after the drug-store chain and health insurer logged earnings ahead of analysts' expectations. Incyte slid after the maker of cancer drugs and other specialty pharmaceuticals forecast 2026 revenue short of Wall Street expectations. Write to Rob Curran at rob.curran@dowjones.com (END) Dow Jones Newswires 02-10-26 1730ET ### Related Stocks - [CVS.US - CVS Health](https://longbridge.com/en/quote/CVS.US.md) - [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md) - [OSCG.US - Leverage Shares 2X Long OSCR Daily ETF](https://longbridge.com/en/quote/OSCG.US.md) - [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md) - [INCY.US - Incyte](https://longbridge.com/en/quote/INCY.US.md) - [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md) - [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md) - [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md) - [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 因塞特醫療｜10-K：2025 財年營收 51.41 億美元超過預期 | | [Link](https://longbridge.com/en/news/275510158.md) | | 德意志銀行維持對阿斯利康（AZN）的賣出評級 | 德意志銀行分析師 Emmanuel Papadakis 對阿斯利康（AstraZeneca，股票代碼：AZN）維持了賣出評級，目標價為 115.00 英鎊。儘管如此，分析師對阿斯利康的共識評級為強烈買入，平均目標價為 15,292.02 英 | [Link](https://longbridge.com/en/news/276058097.md) | | 在分析師的積極評價和研發管線取得進展後，評估 MBX Biosciences（MBX）的估值 | MBX Biosciences (MBX) 因其肽療法管線的進展和分析師的積極情緒而受到關注。目前股價為 38.09 美元，過去 30 天股價下跌了 6.02%，但在 90 天內上漲了 48.73%，反映出強勁的長期動能。MBX 的市淨率為 | [Link](https://longbridge.com/en/news/276031364.md) | | Oscar Health 第四季度的收入未能達到分析師的預期 | Oscar Health 第四季度的收入和調整後的息税折舊攤銷前利潤（EBITDA）未能達到分析師的預期，收入為 28.1 億美元，而預期為 31.2 億美元。該公司已進入一項 4.75 億美元的循環信貸額度，以增強其資產負債表。對於 20 | [Link](https://longbridge.com/en/news/275445989.md) | | Oscar Health 預計儘管在 2025 年會有虧損，但在 2026 年將實現增長 | Oscar Health 已獲得 4.75 億美元的循環信貸額度，以增強流動性並支持增長。儘管預計 2025 年收入將增加至 117 億美元，但由於醫療成本高企，公司報告了 3.964 億美元的運營虧損。Oscar 預計 2026 年收入將 | [Link](https://longbridge.com/en/news/275451700.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.